Gian Luca Forni

List of Publications by Year
in descending order

141 papers	5,352 citations	109321 35 h-index	88630 70 g-index
141 all docs	141 docs citations	141 times ranked	4936 citing authors

#	Article	IF	Citations
1	Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 2004, 89, 1187-93.	3.5	772
2	On T2* Magnetic Resonance and Cardiac Iron. Circulation, 2011, 123, 1519-1528.	1.6	381
3	Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 2006, 107, 3733-3737.	1.4	338
4	A randomised comparison of deferasiroxversusdeferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology, 2007, 136, 501-508.	2.5	255
5	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176.	2.2	210
6	Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 2006, 91, 873-80.	3.5	210
7	Hepatocellular carcinoma in the thalassaemia syndromes. British Journal of Haematology, 2004, 124, 114-117.	2.5	147
8	A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica, 2011, 96, 1708-1711.	3.5	122
9	Changing patterns in the epidemiology of Î²â€thalassemia. European Journal of Haematology, 2020, 105, 692-703.	2.2	122
10	Multiâ€gene panel testing improves diagnosis and management of patients with hereditary anemias. American Journal of Hematology, 2018, 93, 672-682.	4.1	117
11	Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica, 2006, 91, 1343-51.	3.5	109
12	Pregnancy and Â-thalassemia: an Italian multicenter experience. Haematologica, 2010, 95, 376-381.	3.5	103
13	Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of Î²-Thalassemia Patients Using Right Heart Catheterization. Circulation, 2014, 129, 338-345.	1.6	101
14	Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica, 2005, 90, 452-8.	3.5	91
15	Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up. Parkinsonism and Related Disorders, 2014, 20, 651-654.	2.2	80
16	Widespread multitissue deletions of the mitochondrial genome in the Pearson marrow-pancreas syndrome. Journal of Pediatrics, 1990, 117, 599-602.	1.8	79
17	Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Movement Disorders, 2008, 23, 904-907.	3.9	70
18	Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. British Journal of Haematology, 2014, 167, 121-126.	2.5	69

#	Article	IF	Citations
19	Longâ€term safety and efficacy of deferasirox (Exjade^{Â®}) for up to 5â€ƒyears in transfusional ironâ€overloaded patients with sickle cell disease. British Journal of Haematology, 2011, 154, 387-397.	2.5	67
20	Genetic and clinical heterogeneity of ferroportin disease. British Journal of Haematology, 2005, 131, 663-670.	2.5	64
21	Sickle cell disease: a review for the internist. Internal and Emergency Medicine, 2019, 14, 1051-1064.	2.0	61
22	Sotatercept, a novel transforming growth factor Î² ligand trap, improves anemia in Î²-thalassemia: a phase II, open-label, dose-finding study. Haematologica, 2019, 104, 477-484.	3.5	61
23	A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. Thrombosis Research, 2020, 193, 170-172.	1.7	57
24	Patient-Reported Outcomes of Deferasirox (ExjadeÂ®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis. Acta Haematologica, 2008, 119, 133-141.	1.4	56
25	<scp>SARSâ€CoV</scp>â€2 infection in beta thalassemia: Preliminary data from the Italian experience. American Journal of Hematology, 2020, 95, E198-E199.	4.1	56
26	Recommendations for diagnosis and treatment of methemoglobinemia. American Journal of Hematology, 2021, 96, 1666-1678.	4.1	56
27	Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica, 2004, 89, 1179-86.	3.5	49
28	A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood, 2012, 119, 3263-3268.	1.4	48
29	Stem Cell Modeling of Neuroferritinopathy Reveals Iron as a Determinant of Senescence and Ferroptosis during Neuronal Aging. Stem Cell Reports, 2019, 13, 832-846.	4.8	46
30	A genetic score for the prediction of beta-thalassemia severity. Haematologica, 2015, 100, 452-457.	3.5	45
31	Treatment of hepatitis C virus infection with directâ€acting antiviral drugs is safe and effective in patients with hemoglobinopathies. American Journal of Hematology, 2017, 92, 1349-1355.	4.1	42
32	Mutational spectrum in congenital dyserythropoietic anemia type II: Identification of 19 novel variants in SEC23B gene. American Journal of Hematology, 2010, 85, 915-920.	4.1	40
33	Daily alternating deferasirox and deferiprone therapy for â€œhardâ€toâ€chelateâ€Î²â€thalassemia major patients. American Journal of Hematology, 2010, 85, 460-461.	4.1	38
34	Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen. Journal of Clinical Pharmacology, 2008, 48, 428-435.	2.0	36
35	Neridronate improves bone mineral density and reduces back pain in Î²â€thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallelâ€arm, openâ€label study. British Journal of Haematology, 2012, 158, 274-282.	2.5	36
36	Changes in the quality of life of people with thalassemia major between 2001 and 2009. Patient Preference and Adherence, 2013, 7, 231.	1.8	36

#	Article	IF	Citations
37	New TFR2 mutations in young Italian patients with hemochromatosis. Haematologica, 2008, 93, 309-310.	3.5	35
38	Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent. Blood Cells, Molecules, and Diseases, 2018, 69, 82-89.	1.4	34
39	CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients. Haematologica, 2012, 97, 1818-1825.	3.5	34
40	Changing patterns of splenectomy in transfusionâ€dependent thalassemia patients. American Journal of Hematology, 2011, 86, 808-810.	4.1	32
41	Management of the aging beta-thalassemia transfusion-dependent population â€“ The Italian experience. Blood Reviews, 2019, 38, 100594.	5.7	32
42	Assessment and management of iron overload in Î²â€thalassaemia major patients during the 21st century: a realâ€life experience from the <scp>I</scp>talian <scp>W</scp>ebthal project. British Journal of Haematology, 2013, 161, 872-883.	2.5	31
43	Management of betaâ€thalassemiaâ€“associated osteoporosis. Annals of the New York Academy of Sciences, 2016, 1368, 73-81.	3.8	31
44	Cholelithiasis in thalassemia major. European Journal of Haematology, 2009, 82, 22-25.	2.2	29
45	Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey. Pediatric Blood and Cancer, 2018, 65, e26774.	1.5	29
46	Response of iron overload to deferasirox in rare transfusionâ€dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. European Journal of Haematology, 2011, 87, 338-348.	2.2	28
47	Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review. Blood Transfusion, 2019, 17, 4-15.	0.4	28
48	Deferasirox effect on renal haemodynamic parameters in patients with transfusionâ€dependent Î² thalassaemia. British Journal of Haematology, 2015, 168, 882-890.	2.5	27
49	Musculoskeletal Manifestations of Chronic Anemias. Seminars in Musculoskeletal Radiology, 2011, 15, 269-280.	0.7	26
50	Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series. International Journal of Molecular Sciences, 2020, 21, 8771.	4.1	25
51	Klotho, a new marker for osteoporosis and muscle strength in Î²-thalassemia major. Blood Cells, Molecules, and Diseases, 2015, 55, 396-401.	1.4	24
52	Current challenges in the management of patients with sickle cell disease â€“ A report of the Italian experience. Orphanet Journal of Rare Diseases, 2019, 14, 120.	2.7	24
53	Access to emergency departments for acute events and identification of sickle cell disease in refugees. Blood, 2019, 133, 2100-2103.	1.4	24
54	The influence of treatment in specialized centers on survival of patients with thalassemia major. American Journal of Hematology, 2009, 84, 317-318.	4.1	23

#	Article	IF	Citations
55	Dyskeratosis Congenita: Unusual Presenting Features Within a Kindred. Pediatric Hematology and Oncology, 1993, 10, 145-149.	0.8	22
56	Complex Modes of Inheritance in Hereditary Red Blood Cell Disorders: A Case Series Study of 155 Patients. Genes, 2021, 12, 958.	2.4	22
57	Diagnostic value of real-time elastography in the assessment of hepatic fibrosis in patients with liver iron overload. European Journal of Radiology, 2013, 82, e755-e761.	2.6	21
58	Standardized T2* Map of a Normal Human Heart to Correct T2* Segmental Artefacts; Myocardial Iron Overload and Fibrosis in Thalassemia IntermediaVersusThalassemia Major Patients and Electrocardiogram Changes in Thalassemia Major Patients. Hemoglobin, 2008, 32, 97-107.	0.8	20
59	Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?. European Journal of Haematology, 2015, 94, 310-317.	2.2	19
60	Patient Affected by Beta-Propeller Protein-Associated Neurodegeneration: A Therapeutic Attempt with Iron Chelation Therapy. Frontiers in Neurology, 2017, 8, 385.	2.4	18
61	Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study. European Journal of Echocardiography, 2011, 12, 242-246.	2.3	16
62	Development of interactive algorithm for clinical management of acute events related to sickle cell disease in emergency department. Orphanet Journal of Rare Diseases, 2014, 9, 91.	2.7	14
63	Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up. Haematologica, 2014, 99, e17-e18.	3.5	14
64	Lack of correlation between heart, liver and pancreas <scp>MRI</scp>â€<scp>R</scp>2*: Results from longâ€term followâ€up in a cohort of adult Î²â€thalassemia major patients. American Journal of Hematology, 2018, 93, E79-E82.	4.1	14
65	Noninvasive liver fibrosis assessment in chronic viral hepatitis C: agreement among 1D transient elastography, 2D shear wave elastography, and magnetic resonance elastography. Abdominal Radiology, 2019, 44, 4011-4021.	2.1	14
66	Fyn specifically Regulates the activity of red cell glucose-6-phosphate-dehydrogenase. Redox Biology, 2020, 36, 101639.	9.0	14
67	A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (Î²)-Thalassemia: Interim Results. Blood, 2013, 122, 3448-3448.	1.4	14
68	Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited. Internal and Emergency Medicine, 2019, 14, 365-370.	2.0	13
69	Efficacy and safety of deferiprone for the treatment of superficial siderosis: results from a long-term observational study. Neurological Sciences, 2019, 40, 1357-1361.	1.9	13
70	Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with Â-thalassemia major. Haematologica, 2013, 98, 555-559.	3.5	12
71	Development of Algorithm for Clinical Management of Sickle Cell Bone Disease: Evidence for a Role of Vertebral Fractures in Patient Follow-up. Journal of Clinical Medicine, 2020, 9, 1601.	2.4	12
72	Quality of Life and Burden of Disease in Italian Patients with Transfusion-Dependent Beta-Thalassemia. Journal of Clinical Medicine, 2022, 11, 15.	2.4	12

#	Article	IF	Citations
73	A new glucose-6-phosphate dehydrogenase variant with congenital nonspherocytic hemolytic anemia (G6PD Genova). Human Genetics, 1990, 84, 337-40.	3.8	11
74	Comparison between different software programs and post-processing techniques for the MRI quantification of liver iron concentration in thalassemia patients. Radiologia Medica, 2016, 121, 751-762.	7.7	11
75	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. Digestive and Liver Disease, 2016, 48, 650-655.	0.9	11
76	Renal safety under longâ€course deferasirox therapy in iron overloaded transfusionâ€dependent Î²â€thalassemia and other anemias. American Journal of Hematology, 2018, 93, E172-E175.	4.1	11
77	Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort. Haematologica, 2022, 107, 467-477.	3.5	11
78	Therapeutic Approaches to Pulmonary Hypertension in Hemoglobinopathies: Efficacy and Safety of Sildenafil in the Treatment of Severe Pulmonary Hypertension in Patients with Hemoglobinopathy. Annals of the New York Academy of Sciences, 2005, 1054, 471-475.	3.8	10
79	Is there a standard-of-care for transfusion therapy in thalassemia?. Current Opinion in Hematology, 2017, 24, 558-564.	2.5	10
80	Mortality in Î²-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization. Blood, 2022, 139, 2080-2083.	1.4	10
81	Typical manifestation of acute congestive heart failure in patients with Thalassaemia major causing diagnostic delay in the emergency room. European Journal of Heart Failure, 2003, 5, 607-608.	7.1	9
82	Transferrin-immune complex disease: A potentially overlooked gammopathy mediated by IgM and IgG. American Journal of Hematology, 2013, 88, 1045-1049.	4.1	9
83	Noninvasive monitoring of liver fibrosis in sickle cell disease: Longitudinal observation of a cohort of adult patients. American Journal of Hematology, 2017, 92, E666-E668.	4.1	9
84	COVID-19 in a Patient with Î²-Thalassemia Major and Severe Pulmonary Arterial Hypertension. Hemoglobin, 2020, 44, 218-220.	0.8	9
85	Hematopoietic Cell Transplantation in Thalassemia and Sickle Cell Disease: Report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000-2017. Blood, 2018, 132, 168-168.	1.4	9
86	Long-Term Efficacy and Safety with Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, in Pediatric Patients.. Blood, 2007, 110, 2774-2774.	1.4	9
87	Efficacy and Safety of 1 Yearâ€™s Treatment with Deferasirox (ExjadeÂ®): Assessment of Regularly Transfused Patients with Diamond-Blackfan Anemia Enrolled in the EPIC Study.. Blood, 2008, 112, 1048-1048.	1.4	9
88	Manual erythroexchange for chronic transfusion therapy in patients with sickle cell syndromes unresponsive to hydroxyurea: A longâ€term followâ€up. American Journal of Hematology, 2010, 85, 974-974.	4.1	8
89	Recommendations for Pregnancy in Rare Inherited Anemias. HemaSphere, 2020, 4, e446.	2.7	8
90	Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study. Blood, 2015, 126, 752-752.	1.4	8

#	Article	IF	Citations
91	Italian patients with hemoglobinopathies exhibit a 5â€fold increase in ageâ€standardized lethality due to SARSâ€CoVâ€2 infection. American Journal of Hematology, 2022, 97, .	4.1	7
92	Acquired iron overload associated with antitransferrin monoclonal immunoglobulin: A case report. American Journal of Hematology, 2008, 83, 932-934.	4.1	6
93	Venous-Like Leg Ulcers without Venous Insufficiency in Congenital Anemia: Successful Treatment Using Compression Bandages. Dermatologic Surgery, 2010, 36, 1336-1340.	0.8	6
94	Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusionâ€dependent thalassemia patients. American Journal of Hematology, 2018, 93, E338-E340.	4.1	6
95	Cumulative Efficacy and Safety of 5-Year Deferasirox (ExjadeÂ®) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial. Blood, 2008, 112, 5413-5413.	1.4	6
96	Thalassaemia is paradoxically associated with a reduced risk of inâ€hospital complications and mortality in COVIDâ€19: Data from an international registry. Journal of Cellular and Molecular Medicine, 2022, 26, 2520-2528.	3.6	6
97	Quantitative Texture Analysis in Twoâ€Dimensional Echocardiography. Echocardiography, 1996, 13, 9-20.	0.9	5
98	Deferasirox (ExjadeÂ®) in Pediatric Patients with Î²-Thalassemia: Update of 4.7-Year Efficacy and Safety from Extension Studies. Blood, 2008, 112, 3883-3883.	1.4	5
99	Iron overloadâ€related heart failure in a patient with transfusionâ€dependent myelodysplastic syndrome reversed by intensive combined chelation therapy. Clinical Case Reports (discontinued), 2015, 3, 952-954.	0.5	4
100	Characterization of ferromagnetic or conductive properties of metallic foreign objects embedded within the human body with magnetic iron detector (MID): Screening patients for MRI. Magnetic Resonance in Medicine, 2015, 73, 2030-2037.	3.0	4
101	Selecting Î²-thalassemia Patients for Gene Therapy: A Decision-making Algorithm. HemaSphere, 2021, 5, e555.	2.7	4
102	SF3B1 Mutation Is an Independent Predictor of Parenchymal Iron Overload in Myelodysplastic Syndromes. Blood, 2015, 126, 1678-1678.	1.4	4
103	Antibodies reacting with Simian virus 40 mimotopes in serum samples from patients with thalassaemia major. Blood Transfusion, 2014, 12, 464-70.	0.4	4
104	Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent Î²-Thalassemia in the BEYOND Trial. Blood, 2021, 138, 3081-3081.	1.4	4
105	Pseudoxanthoma Elasticum-Like in Î²-Thalassemia Major, a matter of Î±-Klotho and Parathyroid Hormone?. Hemoglobin, 2017, 41, 254-259.	0.8	3
106	Manual erythroexchange in sickle cell disease: multicenter validation of a protocol predictive of volume to exchange and hemoglobin values. Annals of Hematology, 2020, 99, 2047-2055.	1.8	3
107	Transfusion Therapy in a Multi-Ethnic Sickle Cell Population Real-World Practice. a Preliminary Data Analysis of Multicentre Survey. Blood, 2018, 132, 2389-2389.	1.4	3
108	A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (ExjadeÂ®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story. Blood, 2019, 134, 4256-4256.	1.4	3

#	Article	IF	Citations
109	Incidence of Pulmonary Hypertension in Haemoglobinopathic Patients without Left Ventricular Disfunction.. Blood, 2005, 106, 2691-2691.	1.4	3
110	Calibration of Myocardial T2* Values in Post-Mortem Hearts.. Blood, 2005, 106, 3837-3837.	1.4	3
111	G6PD deficiency-related chronic hemolysis treated with splenectomy: A case report. American Journal of Hematology, 1994, 47, 146-147.	4.1	2
112	Selecting ÃŸ-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm. Blood, 2019, 134, 972-972.	1.4	2
113	Neridronate (NE) for the Treatment of Osteoporosis In Patients with Î²-Thalassemia: Results from an Italian Multicenter Randomized, Open Label, Phase II Trial. Blood, 2010, 116, 4282-4282.	1.4	2
114	Two-Year Renal Hemodynamic Effects of Deferasirox in Patients with Transfusion-Dependent Î²-Thalassemia. Blood, 2012, 120, 3257-3257.	1.4	2
115	Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi-Center Randomized Clinical Trial. Blood, 2014, 124, 1354-1354.	1.4	2
116	Renal Safety after More Than a Decade of Deferasirox Use in Patients with Transfusional Hemosiderosis. Blood, 2016, 128, 2466-2466.	1.4	2
117	Changing patterns of thalassaemia in Italy: a WebThal perspective. Blood Transfusion, 2021, 19, 261-268.	0.4	2
118	Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy. Frontiers in Medicine, 2022, 9, 832154.	2.6	2
119	Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies. Journal of Clinical Medicine, 2022, 11, 1826.	2.4	2
120	Long-Term Safety and Efficacy of Deferasirox (ExjadeÂ®) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years. Blood, 2010, 116, 845-845.	1.4	1
121	The Increased Burden of Sickle Cell Disease in Italy: Findings from the Greatalys (Generating Real) Tj ETQq1 1 0.784314 rgBT /Overloc	1.4	1
122	Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia. HemaSphere, 2021, 5, e660.	2.7	1
123	Thalassemia Is Paradoxically Associated with a Reduced Risk of In-Hospital Complications and Mortality in COVID-19: Data from an International Registry. SSRN Electronic Journal, 0, , .	0.4	0
124	Preliminary Results of Full Body Iron Overload Measurement by a Magnetic Susceptometer.. Blood, 2005, 106, 3714-3714.	1.4	0
125	Multi-Centre Validation of the Cardiovascular Magnetic Resonance Multi Breath-Hold T2* Technique for Myocardial Iron Quantification in Thalassaemia Major.. Blood, 2005, 106, 3828-3828.	1.4	0
126	Cardiovascular Involvement in Thalassemia Major Patients: WEB-THALÂ® Data Analysis (A Web-Based) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.4	0

#	Article	IF	Citations
127	Cardiac and Liver Magnetic Resonance Characterization of Thalassemia Intermedia Patients: A Comparative Multicenter Study Versus Thalassemia Major Patients. Blood, 2008, 112, 5421-5421.	1.4	0
128	Effect of Iron Chelators on Cardiac Iron Assessed by MR T2* in Thalassemia Major. Blood, 2008, 112, 3886-3886.	1.4	0
129	Prevalence, Clinical and Instrumental Correlates of Myocardial Fibrosis and Necrosis by Delayed Contrast Enhancement Cardiovascular Magnetic Resonace in Thalassemia Major Patients. Blood, 2008, 112, 5424-5424.	1.4	0
130	Manual Erythro-Exchange (MEEX) to Prevent Complications of Sickle Cell Disease in Patients Unresponsive to Hydroxyurea: A Long-Term Follow-up. Blood, 2008, 112, 4815-4815.	1.4	0
131	Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study. Blood, 2011, 118, 690-690.	1.4	0
132	Iron Chelation Therapy and Mobilization of Hematopoietic Peripheral Progenitors in Patients with Î²-Thalassemia Major. Blood, 2012, 120, 5178-5178.	1.4	0
133	Estimation of the Prevalence of Pulmonary Artery Hypertension in a Large Group of Î²-Thalassemia Patients Using Right Heart Catheterization. Blood, 2012, 120, 3262-3262.	1.4	0
134	Nonrandom Xâ€Chromosome Inactivation in Hemopoietic Cells from Carriers of Dyskeratosis Congenita. American Journal of Human Genetics, 1997, 61, 458-461.	6.2	0
135	The Impact of Comorbidities on Clinical Outcome of Patients with Myelodysplastic Syndromes: A Real-Life Survey. Blood, 2014, 124, 4668-4668.	1.4	0
136	The Prognostic Role of Diabetes Mellitus for Cardiac Complications in a Large Cohort of Well Treated Thalassemia Major Patients. Blood, 2014, 124, 4043-4043.	1.4	0
137	Safety and Efficacy of Direct-Acting Antiviral Drugs in Patients with Haemoglobinophaties and Chronic Hepatitis C Infection. Blood, 2016, 128, 3627-3627.	1.4	0
138	GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia. Blood, 2018, 132, 3633-3633.	1.4	0
139	Fyn Specifically Regulates the Activity of Red Cell Glucose-6-Phosphate-Dehydrogenase. Blood, 2019, 134, 3527-3527.	1.4	0
140	Hemoglobinopathies and Cancer: Preliminary Results of an Italian Multicenter Experience. Blood, 2021, 138, 946-946.	1.4	0
141	Tricuspid-valve regurgitant jet velocity as a risk factor for death in Î²-Thalassemia. Haematologica, 2022, , .	3.5	0